Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1982 1
1987 1
1988 3
1989 7
1991 3
1992 6
1993 3
1994 8
1995 13
1996 3
1997 9
1998 10
1999 10
2000 7
2001 8
2002 11
2003 10
2004 11
2005 11
2006 6
2007 9
2008 11
2009 16
2010 9
2011 13
2012 12
2013 4
2014 8
2015 11
2016 11
2017 16
2018 8
2019 12
2020 15
2021 10
2022 7
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Results by year

Filters applied: . Clear all
Page 1
Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Lu X, et al. Among authors: troncoso p. Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Nature. 2017. PMID: 28321130 Free PMC article.
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: troncoso p. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Corn PG, et al. Among authors: troncoso p. Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9. Lancet Oncol. 2019. PMID: 31515154 Free PMC article. Clinical Trial.
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Li L, et al. Among authors: troncoso p. Sci Signal. 2017 May 23;10(480):eaam7479. doi: 10.1126/scisignal.aam7479. Sci Signal. 2017. PMID: 28536297 Free PMC article.
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Siddiqui BA, et al. Among authors: troncoso p. J Immunother Cancer. 2023 Mar;11(3):e006262. doi: 10.1136/jitc-2022-006262. J Immunother Cancer. 2023. PMID: 36948506 Free PMC article.
Correlation of in-vivo imaging with histopathology: A review.
Sen A, Troncoso P, Venkatesan A, Pagel MD, Nijkamp JA, He Y, Lesage AC, Woodland M, Brock KK. Sen A, et al. Among authors: troncoso p. Eur J Radiol. 2021 Nov;144:109964. doi: 10.1016/j.ejrad.2021.109964. Epub 2021 Sep 21. Eur J Radiol. 2021. PMID: 34619617 Review.
Detection and Treatment of Primary Prostatic Melanoma.
Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF. Li R, et al. Among authors: troncoso p. Urology. 2019 Jan;123:16-19. doi: 10.1016/j.urology.2018.08.035. Epub 2018 Sep 5. Urology. 2019. PMID: 30195014 Review.
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.
Wu C, Peng S, Pilié PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. Wu C, et al. Among authors: troncoso p. Mol Cancer Ther. 2021 Sep;20(9):1680-1691. doi: 10.1158/1535-7163.MCT-20-0848. Epub 2021 Jun 22. Mol Cancer Ther. 2021. PMID: 34158347 Free PMC article.
Soft-tissue tumors.
Troncoso P, Ordoñez NG, Mackay B. Troncoso P, et al. Clin Lab Med. 1987 Mar;7(1):249-60. Clin Lab Med. 1987. PMID: 3549128
285 results